Search global stocks & ETFs...Ctrl K
Learn Mode
Gilead Sciences, IncGILD
$125.97
-$0.37 (-0.293%)
$126.00
$0.03 (0.021%)
GILD
Stock Profile
07-30
Recommended Metric
Score Card
Explore Scores Tab
3.82
Good
Valuation Score
Key Score
3.00
Average
Management
3.00
Average
Growth
4.00
Good
Profitability
3.00
Average
Fin. Health
3.00
Average
Dividends
5.00
Very Good
Analyst
5.00
Very Good
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$125.97
Baseline
High
$189.00
▲
50.04%
Avg
$161.68
▲
28.35%
Low
$123.22
▼
-2.18%
Analyst Ratings based on 39 Analysts
Strong Buy
1128%
Buy
2154%
Hold
718%
Sell
000%
Strong Sell
000%
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.Read More